Potent preclinical impact of metronomic low-dose oral topotecan combined with the antiangiogenic drug pazopanib for the treatment of ovarian cancer.

@article{Hashimoto2010PotentPI,
  title={Potent preclinical impact of metronomic low-dose oral topotecan combined with the antiangiogenic drug pazopanib for the treatment of ovarian cancer.},
  author={Kae Hashimoto and S. E. P. Man and Ping Xu and William R Cruz-Munoz and Terence Tang and Rakesh Kumar and Robert S. Kerbel},
  journal={Molecular cancer therapeutics},
  year={2010},
  volume={9 4},
  pages={
          996-1006
        }
}
Low-dose metronomic chemotherapy has shown promising activity in many preclinical and some phase II clinical studies involving various tumor types. To evaluate further the potential therapeutic impact of metronomic chemotherapy for ovarian cancer, we developed a preclinical model of advanced human ovarian cancer and tested various low-dose metronomic chemotherapy regimens alone or in concurrent combination with an antiangiogenic drug, pazopanib. Clones of the SKOV-3 human ovarian carcinoma cell… CONTINUE READING

From This Paper

Figures, tables, and topics from this paper.

Citations

Publications citing this paper.
SHOWING 1-10 OF 50 CITATIONS

FILTER CITATIONS BY YEAR

2010
2018

CITATION STATISTICS

  • 5 Highly Influenced Citations

  • Averaged 5 Citations per year over the last 3 years

References

Publications referenced by this paper.
SHOWING 1-10 OF 56 REFERENCES

The optimal biological dose of metronomic chemotherapy regimens is associated with maximum antiangiogenic activity

  • Y Shaked, U Emmengger, S Man
  • Blood
  • 2005
Highly Influential
4 Excerpts

A randomized, double-blind phase III study of pazopanib in treatment-naive and cytokinepretreated patients with advanced renal cell carcinoma

  • CN Sternberg, C Szczylic, E Lee
  • J Clin Oncol ;27:abstract
  • 2009

Similar Papers

Loading similar papers…